icon-account icon-glass

Pregabalin Withdrawal and Tapering Help

Call Point of Return for pregabalin weaning Help   


Searching for how to taper off Pregabalin safely? Have you tried to Get Off Pregabalin only to suffer symptoms that made it too challenging?  Are you afraid that you will not be able to get off Pregabalin?  Our nonprofit has helped people in 82 countries and throughout the United States to Wean Off Pregabalin using a holistic approach to help ease Pregabalin Withdrawal Symptoms.  Our success has freed thousands over 15 years and we can help you taper off Pregabalin safely.  Pregabalin has similar side effects and withdrawal profile as benzodiazepines, so its critical to not only Wean off Pregabalin but also to assist in supporting healing so you stay off Pregabalin.  Seizure risk is a concern if Pregabalin is withdrawn too rapidly. Don't do this alone, let our experts help guide you throughout your Pregabalin Taper. CONTACT us for a free consultation.



pregabalin withdrawal help  

Our Pregabalin weaning program is a slow taper that allows you to safely step down from Pregabalin under the guidance of Our Team, Your Physician and Pharmacist. The Pre-Taper is for Symptom Relief. You will not wean Pregabalin until you feel better. This is where our Advanced Nutraceuticals are critical. Point of Return provides healthy, Drug-Free Strategies to help ease Pregabalin withdrawal and support well-being*

Our areas of expertise are Antidepressants, Benzodiazepines, Sleeping Pills and Painkillers on a case-by-case basis. Our In-Home programs are individualized based on your situation. An assessment is done once you start the Pregabalin Withdrawal Program which allows us to individualize your gameplan based on age; length of time on the medications; health challenges; lifestyle, stress levels; additional medications; and interactions. Don't Wean Pregabalin alone, work with our Prescription Drug Experts.

Imagine being Free of Pregabalin Dependency 

- Proven Program completed In-Home with Expert Guidance

- Slowly Wean off Pregabalin

- All-Natural Nutraceuticals to help Ease Pregabalin Withdrawal

- Professional information on interactions

- Free Mentoring on our 24/7 private Discussion Board

- Free Assessment Upon Starting our Program (a $400 value)

      Enter Discount Code BenzoFree for FREE Ground Shipping on your Withdrawal Program *USA & Canada Only




      Gretchen - how to taper off Pregabalin safely

      Point of Return saved me and I will be forever grateful for the work you put into this so people like me can have a quality of life during the taper and off the drug! More...                          

      Gretchen (Withdrawal Success Story)

      Diane - Pregabalin withdrawal

      I just wanted to let you know that I'm doing well - thanks to your program. I don't think I could have ever done it alone. Please thank everyone in the office for me.  I am deeply grateful to you all. More...

      Diane (Withdrawal Success Story)

      Jeff - how to taper off Pregabalin safely

      Between my faith in God and the help of Point of Return, I have been Ambien and Xanax (Alprazolam) free! More...

      Jeff (Withdrawal Success Story )

      Point of Return was with me Every step of the way, shedding light on such a dark period of my life.  Point of Return isn't just a Withdrawal Program, it's a Lifestyle.

      —Jessica (Withdrawal Success Story)

                                       using a Natural Approach

      Pregabalin withdrawal team

      Our team has survived psychoactive drug withdrawal and healed.  More...

      how to taper off Pregabalin safely anywhere in the world

        We have helped people in 78 countries and in every state of the USA. More...

      Pregabalin withdrawal media coverage

      We have extensive media coverage; television, print, radio. More...


      Message sent, thanks!

      Pregabalin Resource Center


        PREGABALIN HISTORY AND INFO  ( link | pdf )


          Pregabalin History and Information

          Pregabalin was approved for use in the United States in 2004.  It was originally developed as a successor drug to Gabapentin. Lyrica (Pregabalin) went generic in 2019 and is available in a number of countries worldwide for the treatment of diabetic neuropathy, neuralgia and central neuropathic pain. Evidence does not support Pregabalin being useful in sciatica, low back pain, migraines or cancer-associated neuropathic pain.

          Pregabalin was found to be only moderately effective for generalized anxiety disorder but the World Federation of Biological Psychiatry recommends other agents, such as SSRIs as first line treatment for Obsessive-Compulsive Disorder (OCD) and Post Traumatic Stress Disorder (PTSD).

          The side effects and withdrawal profile for Pregabalin is similar to Benzodiazepines and a rapid cessation can cause a seizure.  Pregabalin can cause both physical and psychological dependence and abruptly stopping, even after short term use, can cause withdrawal symptoms that include anxiety, diarrhea, flu-like symptoms, major depression, increase in pain, nervousness, convulsions, hyperhidrosis and extreme dizziness. The manufacturer recommends a gradual reduction schedule yet none is provided in the product insert.

          Pregabalin can interact with opioids, benzodiazepines, barbituates, alcohol and many other drugs.

          Pregabalin Withdrawal Symptoms, Side Effects, Adverse Reactions


          anger, anxiety, body aches, chills, crying spells, depersonalization, depression, diarrhea, dizziness, fatigue, flu-like symptoms, headache, hot flashes, irritability, itching, joint pain, mood swings, muscle spasms, nausea, panic attacks, poor concentration, seizures, shortness of breath, sleep issues, stomach pain, suicidal thinking, sweating, vision issues, weight loss


          loss of muscle coordination, blurred vision, difficulty concentrating, dizziness, dry mouth, fluid retention in legs, feet, arms, hands, weight gain, infection, decreased blood platelets, constipation, confusion, backache, generalized weakness, excessive saliva production, head pain, increased hunger, inflammation, joint pain, itching, memory impairment, muscle spasm, numbness, twitching, hives, kidney stones, low blood sugar, ringing in ears, suicidal thoughts, wheezing, double vision, behavioral problems, anxiousness, bronchitis, bruising, chest pain, skin rash, vision issues, depersonalization, diarrhea, enlarged breasts, fever, gas, flu-like symptoms, leg cramps, low energy, tremor, nervousness, nausea, pink eye, skin redness, vomiting, breathing issues


          Severe: visual impairment, angioedema, laryngeal edema, heart failure, oliguria, cholecystitis, pancreatitis, GI bleeding, retinal edema, ocular hemorrhage, suicidal ideation, epididymitis, coma, pulmonary edema, renal failure (unspecified), increased intracranial pressure, pulmonary fibrosis, apnea, ventricular fibrillation, retroperitoneal fibrosis, esophageal ulceration, acute cerebellar syndrome, torticollis, anaphylactoid reactions, skin necrosis, Stevens-Johnson syndrome, skin atrophy, exfoliative dermatitis, papilledema, keratitis, night blindness, optic atrophy, uveitis, keratoconjunctivitis, Guillain-Barre syndrome , rhabdomyolysis, new primary malignancy

          Moderate: peripheral edema, ataxia, blurred vision, amblyopia, euphoria, constipation, peripheral neuropathy, edema, confusion, amnesia, myasthenia, chest pain (unspecified), memory impairment, myoclonia, fluid retention, hypoglycemia, dyspnea, thrombocytopenia, urinary incontinence, skin ulcer, hypotension, hypertension, depression, elevated hepatic enzymes, hematuria, dysuria, orthostatic hypotension, phlebitis, palpitations, ejaculation dysfunction, urinary retention, hyperacusis, oral ulceration, gastritis, colitis, melena, dysphagia, esophagitis, cholelithiasis, hypotonia, hyperalgesia, hyperesthesia, contact dermatitis, blepharitis, photophobia, lymphadenopathy, eosinophilia, anemia, leukopenia, aphasia, dysarthria, hostility, hallucinations, proteinuria, crystalluria, ascites, glycosuria, cervicitis, sinus tachycardia, dyspareunia, stomatitis, dyskinesia, dystonic reaction, trismus, neuritis, exophthalmos, iritis, polycythemia, encephalopath, mania, delirium, psychosis, impotence (erectile dysfunction), hypertonia, nystagmus, conjunctivitis, wheezing, myopathy, physiological dependence, withdrawal, infertility

          Mild: dizziness, drowsiness, weight gain, xerostomia, headache, infection, diplopia, fatigue, tremor, appetite stimulation, pharyngitis, asthenia, sinusitis, arthralgia, nausea, lethargy, hypersalivation, back pain, vertigo, insomnia, flatulence, vomiting, hypoesthesia, anxiety, abdominal pain, diarrhea, amenorrhea, menorrhagia, leukorrhea, cough, syncope, dysmenorrhea, chills, pelvic pain, libido increase, dysgeusia, hyperkinesis, rash, urticaria, alopecia, vesicular rash, xerosis, hirsutism, photosensitivity, xerophthalmia, leukocytosis, irritability, malaise, agitation, hiccups, yawning, parosmia, psychomotor impairment, miosis, ptosis, mydriasis, purpura, paranoia, orgasm dysfunction, muscle cramps, increased urinary frequency, myalgia, libido decrease, fever, tinnitus, paresthesias, pruritus, ecchymosis, breast enlargement, gynecomastia


          Depression, suicidal ideation

          Antiepileptic drugs (AEDs), including Pregabalin, increase the risk of suicidal ideation, thoughts or behavior in patients taking these drugs for any indication. Patients treated with any AED for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior. Pooled analyses of 199 placebo-controlled clinical trials (mono- and adjunctive therapy) of 11 different AEDs showed that patients randomized to 1 of the AEDs had approximately twice the risk (adjusted RR 1.8, 95% CI:1.2, 2.7) of suicidal thinking or behavior compared to patients taking placebo. In these trials, which had a median treatment duration of 12 weeks, the estimated incidence rate of suicidal behavior or ideation among 27,863 AED-treated patients was 0.43%, compared to 0.24% among 16,029 placebo-treated patients, representing an increase of approximately 1 case of suicidal thinking or behavior for every 530 patients treated. There were 4 suicides in drug-treated patients in the trials and none in placebo-treated patients, but the number is too small to allow any conclusion about drug effect on suicide. The increased risk of suicidal thoughts or behavior was observed as early as 1 week after starting drug treatment and persisted for the duration of treatment assessed. Because most trials included in the analysis did not extend beyond 24 weeks, the risk of suicidal thoughts or behavior beyond 24 weeks could not be assessed. The risk of suicidal thoughts or behavior was generally consistent among drugs in the data analyzed. The finding of increased risk with AEDs of varying mechanisms of action and across a range of indications suggests that the risk applies to all AEDs used for any indication. The risk did not vary substantially by age (5 to 100 years of age) in the clinical trials analyzed. The relative risk for suicidal thoughts or behavior was higher in clinical trials for epilepsy than in clinical trials for psychiatric or other conditions, but the absolute risk differences were similar for the epilepsy and psychiatric indications. Epilepsy and many other illnesses for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior. Should suicidal thoughts and behavior emerge consider whether the emergence of these symptoms in any given patient may be related to the illness being treated. Closely monitor patients for emerging or worsening depression or suicidal thoughts/behavior. Patients and caregivers should be informed of the increased risk of suicidal thoughts and behaviors and should be advised to immediately report the emergence or worsening of depression, the emergence of suicidal thoughts or behavior, thoughts of self-harm, or other unusual changes in mood or behavior. Pregabalin should be prescribed in the smallest quantity consistent with good patient management in order to reduce the risk of overdose.

          Abrupt discontinuation
          Abrupt discontinuation of Pregabalin after prolonged use should be avoided to reduce the risk for withdrawal seizures or adverse effects such as insomnia, nausea, headache, anxiety, hyperhidrosis, and diarrhea. Withdraw pregabalin slowly, using a gradual dose-tapering schedule over a minimum of 1 week.

          Pregabalin References and Other Information

          According to the FDA (Food and Drug Administration):

          Increased seizure frequency or other adverse reactions may occur if LYRICA (Pregabalin) is rapidly discontinued. Withdraw LYRICA gradually over a minimum of 1 week. (5.3)

          Antiepileptic drugs,including LYRICA (Pregabalin), increase the risk of suicidal thoughts or behavior. (5.4)

          LYRICA (Pregabalin) may cause peripheral edema. Exercise caution when co­ administering LYRICA (Pregabalin) and thiazolidinedione anti diabetic agents.(5.5)

          LYRICA (Pregabalin)may cause dizziness and somnolence and impair patients’ ability to drive or operate machinery.

          ----------------------------------ADVERSE REACTIONS ----------------------------------

          Most common adverse reactions (greater than or equal to 5% and twice placebo) in adults are dizziness, somnolence, dry mouth, edema, blurred vision,weight gain,and thinking abnormal( primarily difficulty with concentration/attention). (6.1)

          Most common adverse reactions (greater than or equal to 5% and twice placebo) in pediatric patients for the treatment of partial onset seizures are increased weight and increased appetite.


          *While great care has been taken in organizing and presenting the material throughout this website, please note that it is provided for informational purposes only and should not be taken as Medical Advice.

          *The statements/info on this website have not been evaluated by the Food and Drug Administration (FDA). The products and labels mentioned / sold are not intended to diagnose, treat, cure, or prevent any disease or illness.

          * Testimonial results may vary person to person.

          *The program outlined in Point of Return is not meant to substitute your doctor, instead it is to be utilized With Your physician to help you with your drug withdrawal process and with his or her consent and support throughout.

          *This program is not meant to cure or prevent any disease or illness.

          *Because prescription medications can cause severe withdrawal reactions, do not stop taking any medication without first consulting your physician. The decision to taper any medication should be discussed with your doctor and done with their consent and support throughout the process. More..